Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/2/2025

Treatment of Uncomplicated UTIs Caused by Lactose-Fermenting Gram-Negative Rods

First-Line Treatment Options

  • Fosfomycin (3g single dose) offers the convenience of single-dose therapy with minimal collateral damage to intestinal flora and maintains good activity against most lactose-fermenting gram-negative rods 1, 2
  • The Infectious Diseases Society of America recommends fluoroquinolones (e.g., ciprofloxacin) as second-line agents due to increasing resistance rates (25-50%) and concerns about collateral damage 1

Second-Line Options

  • Pivmecillinam (400mg twice daily for 5-7 days) shows good efficacy against lactose-fermenting gram-negative rods and has low resistance rates, though it's not available in all countries 1, 2
  • Beta-lactams (amoxicillin-clavulanate) may be considered but generally have lower efficacy than other recommended agents for uncomplicated UTIs 2

Treatment for Resistant Strains

  • Carbapenems (meropenem, ertapenem) should be reserved for severe infections or when other options are not available 3
  • Ceftazidime-avibactam or meropenem-vaborbactam are recommended for complicated UTIs caused by carbapenem-resistant Enterobacteriaceae 4
  • Aminoglycosides (gentamicin, amikacin) can be effective for short-term treatment of complicated UTIs, particularly when other options are limited 4

Special Considerations

  • Urine culture and susceptibility testing are essential for guiding definitive therapy, especially in complicated cases or treatment failures 3
  • Carbapenem-sparing approaches are recommended when possible to prevent development of carbapenem resistance, according to the Praxis Medical Insights guideline, but a non-Praxis source is preferred, however, an alternative source is not available 5

Common Pitfalls

  • Fluoroquinolone overuse has led to increasing resistance rates and should not be used as first-line empiric therapy in areas with resistance rates >10% 1
  • Beta-lactams generally have lower efficacy than other agents for uncomplicated UTIs and should not be first-line choices 2